The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

MBX Biosciences, Inc.’s MBX share price has dipped by 14.00%, which has investors questioning if this is right time to buy.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.